Stryker (SYK) – Analysts’ Recent Ratings Changes

Stryker (NYSE: SYK) has recently received a number of price target changes and ratings updates:

• 12/12/2024 – Stryker had its price target raised by analysts at Needham & Company LLC from $409.00 to $442.00. They now have a “buy” rating on the stock.
• 12/11/2024 – Stryker had its price target raised by analysts at Wells Fargo & Company from $405.00 to $427.00. They now have an “overweight” rating on the stock.
• 12/11/2024 – Stryker had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $425.00 price target on the stock, up previously from $400.00.
• 12/11/2024 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 12/11/2024 – Stryker had its price target raised by analysts at Citigroup Inc. from $411.00 to $450.00. They now have a “buy” rating on the stock.
• 12/2/2024 – Stryker was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $445.00 price target on the stock, up previously from $370.00.
• 11/22/2024 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/14/2024 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/6/2024 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/31/2024 – Stryker had its price target raised by analysts at Barclays PLC from $402.00 to $418.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Stryker had its price target raised by analysts at Citigroup Inc. from $406.00 to $411.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Stryker had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $420.00 price target on the stock, up previously from $380.00.
• 10/30/2024 – Stryker had its price target raised by analysts at JPMorgan Chase & Co. from $375.00 to $420.00. They now have an “overweight” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Wells Fargo & Company from $381.00 to $405.00. They now have an “overweight” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Royal Bank of Canada from $386.00 to $400.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Evercore ISI from $380.00 to $384.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Robert W. Baird from $378.00 to $405.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at UBS Group AG from $366.00 to $370.00. They now have a “neutral” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Truist Financial Co. from $370.00 to $380.00. They now have a “hold” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at BTIG Research from $383.00 to $394.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Canaccord Genuity Group Inc. from $360.00 to $400.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Needham & Company LLC from $393.00 to $409.00. They now have a “buy” rating on the stock.

Stryker Trading Down 0.5 %

NYSE:SYK opened at $370.75 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a 50-day simple moving average of $374.31 and a 200-day simple moving average of $355.57. Stryker Co. has a one year low of $288.15 and a one year high of $398.20. The firm has a market cap of $141.34 billion, a P/E ratio of 39.74, a P/E/G ratio of 2.82 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.46 EPS. Equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. Stryker’s dividend payout ratio (DPR) is 36.01%.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Dunhill Financial LLC increased its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Centennial Bank AR grew its position in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares during the period. Darwin Wealth Management LLC purchased a new position in shares of Stryker in the 3rd quarter valued at about $36,000. Hara Capital LLC purchased a new position in Stryker during the third quarter worth approximately $42,000. Finally, HBW Advisory Services LLC purchased a new position in Stryker during the third quarter worth approximately $42,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.